MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413081 | Name: Clinprost

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clinprost is a Vasodilator (peripheral), Platelet aggregation inhibitor, and Prostaglandin I2 receptor agonist

Chemical Structure

Clinprost
Clinprost
CAS#88931-51-5

Theoretical Analysis

MedKoo Cat#: 413081

Name: Clinprost

CAS#: 88931-51-5

Chemical Formula: C22H36O4

Exact Mass: 364.2614

Molecular Weight: 364.53

Elemental Analysis: C, 72.49; H, 9.95; O, 17.56

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Clinprost; TEI 9090; TEI9090; TEI-9090; TTC909; TTC-909; TTC 909
IUPAC/Chemical Name
(+)-Methyl-(3aS,5R,6R,6aS)-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-((E)-(3S)-3-hydroxy-1-octenyl)-2-pentalenevalerate
InChi Key
QIGRQPVOWVHYBT-KABTVRTISA-N
InChi Code
InChI=1S/C22H36O4/c1-3-4-5-9-18(23)11-12-19-20-14-16(13-17(20)15-21(19)24)8-6-7-10-22(25)26-2/h11-13,17-21,23-24H,3-10,14-15H2,1-2H3/b12-11+/t17-,18-,19+,20-,21+/m0/s1
SMILES Code
O=C(OC)CCCCC1=C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)CCCCC)[C@@]2([H])C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 364.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Umekubo N, Hayashi Y. Pot-Economical Total Synthesis of Clinprost. Org Lett. 2020 Dec 4;22(23):9365-9370. doi: 10.1021/acs.orglett.0c03616. Epub 2020 Nov 24. PMID: 33231082. 2: Minagawa T, Sakanaka K, Inaba S, Sai Y, Tamai I, Suwa T, Tsuji A. Blood- brain-barrier transport of lipid microspheres containing clinprost, a prostaglandin I2 analogue. J Pharm Pharmacol. 1996 Oct;48(10):1016-22. doi: 10.1111/j.2042-7158.1996.tb05893.x. PMID: 8953502. 3: Cacione DG, Macedo CR, Baptista-Silva JC. Pharmacological treatment for Buerger's disease. Cochrane Database Syst Rev. 2016 Mar 11;3(3):CD011033. doi: 10.1002/14651858.CD011033.pub3. Update in: Cochrane Database Syst Rev. 2020 May 4;5:CD011033. PMID: 26967103; PMCID: PMC7104255. 4: Cacione DG, Macedo CR, do Carmo Novaes F, Baptista-Silva JC. Pharmacological treatment for Buerger's disease. Cochrane Database Syst Rev. 2020 May 4;5(5):CD011033. doi: 10.1002/14651858.CD011033.pub4. PMID: 32364620; PMCID: PMC7197514. 5: Nagy EE, Hyatt IF, Gettys KE, Yeazell ST, Frempong SK Jr, Croatt MP. Sequential Pd(0)-, Rh(I)-, and Ru(II)-catalyzed reactions in a nine-step synthesis of clinprost. Org Lett. 2013 Feb 1;15(3):586-9. doi: 10.1021/ol303402e. Epub 2013 Jan 17. PMID: 23327495. 6: Cacione DG, Baptista-Silva JC, Macedo CR. Pharmacological treatment for Buerger's disease. Cochrane Database Syst Rev. 2016 Feb 1;2:CD011033. doi: 10.1002/14651858.CD011033.pub2. Update in: Cochrane Database Syst Rev. 2016;3:CD011033. PMID: 26828199. 7: Karasawa Y, Hitomi T, Komiyama H, Isobe Y, Kobayashi T, Yoshida S, Nakaike S, Araki H. Effect of TTC-909 in a middle cerebral artery thrombosis model in stroke-prone spontaneously hypertensive rats. Eur J Pharmacol. 2002 Aug 2;449(1-2):127-133. doi: 10.1016/s0014-2999(02)01945-3. PMID: 12163116. 8: Yae T, Araki H, O-ogami Y, Iwasaki K, Tanabe H, Fujiwara M. Effects of the isocarbacyclin methyl ester clinprost incorporated into lipid microspheres, in focal ischemia of stroke-prone spontaneously hypertensive rats. Arzneimittelforschung. 1997 Nov;47(11):1200-3. PMID: 9428973. 9: Karasawa Y, Komiyama H, Yoshida S, Hino N, Katsuura Y, Nakaike S, Araki H. Effect of TTC-909 on cerebral infarction following permanent occlusion of the middle cerebral artery in stroke prone spontaneously hypertensive rats. J Pharmacol Sci. 2003 Apr;91(4):305-12. doi: 10.1254/jphs.91.305. PMID: 12719659. 10: Matsuda S, Wen TC, Karasawa Y, Araki H, Otsuka H, Ishihara K, Sakanaka M. Protective effect of a prostaglandin I2 analog, TEI-7165, on ischemic neuronal damage in gerbils. Brain Res. 1997 Sep 26;769(2):321-8. doi: 10.1016/s0006-8993(97)00724-5. PMID: 9374201.